Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study-Reference-Cited by-同舟云学术

Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study

Published:2020-03 Issue:3 Volume:156 Page:523-529
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Brewer Molly,Angioli Roberto,Scambia Giovani,Lorusso Domenica,Terranova Corrado,Panici Pierluigi Benedetti,Raspagliesi Francesco,Scollo Paolo,Plotti Francessco,Ferrandina Gabriella,Salutari Vanda,Ricci Caterina,Braly Patricia,Holloway Robert,Method Michael,Madiyalakan Madi,Bayever Eliel,Nicodemus Christopher

Funder

OncoQuest, Inc.

Publisher

Elsevier BV

Subject

Obstetrics and Gynaecology,Oncology

Reference18 articles.

1. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer;McGuire;N. Engl. J. Med.,1996

2. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the gynecologic cancer intergroup;Bookman;J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.,2009

3. Comparison of survival between upfront primary debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomized trial: JCOG0602;Onda;J. Clin. Oncol.,2018

4. AGO-OVAR 16: A phase III study to evaluate the efficacy and safety of pazopanib (PZ) monotherapy versus placebo in women who have not progressed after first line chemotherapy for epithelial ovarian, fallopian tube, or primary peritoneal cancer—Overall survival (OS) results.

5. Incorporation of bevacizumab in the primary treatment of ovarian cancer;Burger;N. Engl. J. Med.,2011

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In silico Identification of MHC Displayed Tumor Associated Peptides in Ovarian Cancer for Multi-Epitope Vaccine Construct;Endocrine, Metabolic & Immune Disorders - Drug Targets;2024-09

2. Ovarian cancer: Diagnosis and treatment strategies (Review);Oncology Letters;2024-07-18

3. OPERA: a phase II trial of oregovomab plus non-platinum chemotherapy in PARP inhibitor/platinum-resistant ovarian cancer;Future Oncology;2024-06-28

4. Fluorescent imaging probes for in vivo ovarian cancer targeted detection and surgery;Medicinal Research Reviews;2024-02-17

5. Front-line chemoimmunotherapy for treating epithelial ovarian cancer: Part II promising results of phase 2 study of paclitaxel-carboplatin-oregovomab regimen;Taiwanese Journal of Obstetrics and Gynecology;2024-01